{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Akero Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"AKRO"},"Address":{"label":"Address","value":"601 GATEWAY BOULEVARD SUITE 350, SOUTH SAN FRANCISCO, California, 94080, United States"},"Phone":{"label":"Phone","value":"+1 650 487-6488"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis."},"CompanyUrl":{"label":"Company Url","value":"https://www.akerotx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andrew Cheng","title":"President, Chief Executive Officer &amp; Director"},{"name":"Jonathan Young","title":"Chief Operating Officer &amp; Executive Vice President"},{"name":"Reshma Shringarpure","title":"Vice President-Clinical Research &amp; Medical Affairs"},{"name":"Timothy Rolph","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}